A groundbreaking collaboration between Karolinska Institutet, Karolinska University Hospital, and SciLifeLab has culminated in the integration of whole genome sequencing into the routine diagnostic workflow for rare diseases at Karolinska University Hospital. This ambitious initiative has resulted in the sequencing of the entire genomes of over 15,000 patients, revolutionizing the diagnostic landscape for rare diseases and yielding genetic diagnoses for approximately 23 percent of these individuals. The insights and outcomes of this extensive decade-long effort are detailed in a recent publication in Genome Medicine.
The innovative diagnostic model developed by these institutions represents a significant leap forward in the clinical application of genomic medicine. Traditionally, diagnosing rare diseases has been hampered by incomplete genetic information, often limited to targeted gene panels or exome sequencing. In contrast, whole genome sequencing (WGS) encompasses the totality of an individual’s genetic material, unlocking insights into coding and non-coding regions alike. The integration of WGS into routine care involved sophisticated coordination among clinicians, geneticists, bioinformaticians, and laboratory scientists—ensuring that each patient’s genomic data is carefully interpreted in the context of their unique clinical presentation.
The sheer scale of this undertaking is remarkable. The study analyzed data from 15,644 patients with suspected rare diseases, uncovering pathogenic or likely pathogenic variants in 3,538 cases. This corresponds to a diagnostic yield of 23 percent, a figure that underscores the immense power and utility of WGS to elucidate underlying genetic etiologies. Importantly, the identified variants spanned more than 1,500 distinct genes, highlighting the profound genetic heterogeneity and complexity intrinsic to rare diseases. Such diversity underlines the necessity of comprehensive genomic approaches rather than conventional, more limited testing.
According to adjunct professor Anna Lindstrand, who is deeply involved in this transformative project, obtaining a genetic diagnosis has profound implications for patients confronted with rare diseases. “For many patients, receiving a precise genetic explanation offers closure and clarity, helping to alleviate uncertainty about their condition. Beyond diagnosis, it equips clinicians with crucial information about potential therapeutic strategies, surveillance, prognostication, and informs family planning decisions,” she states. This holistic benefit resonates across clinical domains and patient ages, fostering more informed and personalized healthcare decisions.
The multidisciplinary approach enabling this success integrates the knowledge of clinical specialists deeply familiar with patient phenotypes, with geneticists who interpret the complex variants uncovered by sequencing. Complementing these roles, bioinformaticians develop and maintain robust computational pipelines to filter, prioritize, and analyze vast amounts of genomic data. Laboratory experts further validate findings, completing a seamless translation of raw sequencing data into clinically actionable results. This model ensures swift turnaround times, which is particularly vital for conditions demanding prompt intervention.
One of the transformative aspects of WGS is its ability to detect genetic variations beyond coding exons to include structural variants, deep intronic mutations, and regulatory region alterations—elements often missed by more conventional sequencing methods. This comprehensive scan is crucial for capturing the molecular underpinnings of a wide span of rare diseases, many of which may present with overlapping or nonspecific clinical symptoms. By detecting such diverse genomic aberrations, WGS expands the diagnostic possibility space, thereby increasing yield and clinical utility.
The patient cohort studied spanned a broad spectrum of rare diseases, affecting multiple medical specialties and including many pediatric cases. This reflects the wide-reaching applicability of WGS across rare disease domains, from congenital metabolic disorders and neuromuscular conditions to severe epilepsies. Intriguingly, many of the diagnosed patients would have otherwise remained without a definitive diagnosis under previous diagnostic paradigms, highlighting the critical advantage of the integrated genomic approach.
Professor Anna Wedell, a prominent figure in the study, emphasizes the transformative clinical impact following diagnosis. “In several cases, including those with congenital metabolic disorders and severe epilepsies, the genetic diagnosis has directly informed targeted treatments. This has enabled clinicians to not only prevent disease progression but also circumvent early mortality—demonstrating the life-saving potential of genomic medicine,” she remarks. Such precision medicine represents a shift from symptom management to proactive, mechanism-based therapies.
Another essential feature of the implemented model is the scalability and adaptability of the diagnostic process. The collaboration has established clearly delineated workflows and communication channels which allow for the tailoring of genomic analyses based on individual phenotypic presentations. By integrating clinical details with genomic data dynamically, the model supports both broad discovery and focused hypothesis-driven analysis—crucial for efficiently managing high patient volumes and maximizing diagnostic efficiency.
Beyond immediate diagnostic gains, this paradigm heralds a broader evolution in healthcare toward precision medicine. By fusing deep clinical expertise with cutting-edge genomic technology, Karolinska’s approach exemplifies the future of personalized care—where treatments and management plans are grounded in a patient’s unique genetic blueprint. The researchers envision that this comprehensive and integrated strategy will serve as a scalable blueprint for national and international implementation, advancing rare disease diagnostics globally.
As whole genome sequencing technologies continue to mature, becoming more affordable and faster, their incorporation into clinical care pathways is set to accelerate. The Karolinska initiative, representing one of the most extensive real-world deployments of WGS to date, offers invaluable data and strategic insights for other institutions aiming to realize similar integration. It further exemplifies how collaborative efforts between academic, clinical, and laboratory entities can overcome logistical and analytical challenges inherent in large-scale genomic medicine.
This landmark study underscores the vital importance of multidisciplinary cooperation and robust infrastructure in enabling genomic advances to translate into tangible patient benefits. By integrating WGS into routine diagnostics over the past decade, Karolinska University Hospital and its partners have not only improved the outlook for thousands of patients with rare diseases but also paved the way for next-generation healthcare models based on precision genetics.
In summary, the Karolinska model exemplifies how advancing genomic technologies combined with specialized clinical expertise can redefine the diagnosis and treatment of rare diseases, bringing hope and clarity to patients and families often lost in a diagnostic odyssey. The study’s findings, now published in Genome Medicine, both celebrate this achievement and set a compelling agenda for future research and clinical practice in genomic medicine.
Subject of Research: People
Article Title: The Genomic Medicine Center Karolinska 10-year report on genome sequencing for rare diseases and a strategy for stepwise clinical implementation
News Publication Date: 30-Mar-2026
Web References: https://doi.org/10.1186/s13073-026-01611-3
Keywords: Genetic disorders, Genetic screening
